Merck-Gilead’s Combined HIV Treatment Sunlenca Shows Positive Results in...
A mid-phase trial featuring Gilead Sciences and Merck & Co.’s once-weekly HIV combination therapy has successfully met its primary 24-week endpoint and surpassed expectations by suppressing the...
View ArticleArcus’ HIF-2a Inhibitor Shows Positive Response Rate in Study
The latest research on Arcus Biosciences’ experimental HIF-2a inhibitor suggests that the firm may provide significant competition to Merck’s Welireg in treating kidney cancer. In the phase 1/1b ARC-20...
View ArticleMarinus to cut workforce and explore options after Ztalmy trial setback
Marinus Pharmaceuticals, a pharmaceutical company, has been dealt a blow after its Seizure drug, Ztalmy, did not reach the primary endpoint in the phase three trial for its treatment of seizures that...
View ArticleGSK Responds to Pfizer’s RSV Approval with Data Aiming for Similar Approval...
Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit certain high-risk subgroups of younger adults and could potentially serve a broader population. This news comes shortly...
View ArticleAfter Roche and Takeda, Novartis steps into the molecular glue space
Roche first entered into an agreement with Orionis Biosciences in 2023 and paid the company up to $2 billion to access its investigational glues targeting challenging goals in neurodegeneration and...
View ArticleAbbVie Completes $1.4B Purchase of Aliada
AbbVie has agreed to spend $1.4 billion to purchase Aliada Therapeutics. Through this acquisition, AbbVie will be able to build upon the first class of anti-amyloid-beta antibodies by gaining ownership...
View ArticleAstellas and Europe Clash Over Approval of Geographic Atrophy Drug Izervay
Izervay by Astellas and Syfovre by Apellis are the major rivals in the United States Geographic Atrophy (GA) market, but both are struggling to enter the European market. Due to EMA’s CHMP second...
View ArticleApellis and Novartis both target rare kidney diseases with new drugs
Apellis Pharmaceuticals and Novartis recently shared data for their rare kidney disease drugs, pegcetacoplan and iptacopan. Both have performed well in treating C3 glomerulopathy (C3G) and improving...
View Article